# Use of thymosin β15 as a urinary biomarker in human prostate cancer

@article{Hutchinson2005UseOT,
title={Use of thymosin $\beta$15 as a urinary biomarker in human prostate cancer},
author={Lloyd M Hutchinson and Eric L. Chang and Christian M. Becker and Mei-Chiung Shih and Mark J. Brice and William DeWolf and Sandra M Gaston and Bruce R. Zetter},
journal={The Prostate},
year={2005},
volume={64}
}
Additional prostate cancer (CaP) biomarkers are needed to increase the accuracy of diagnosis and to identify patients at risk of recurrence. In tissue‐based assays, thymosin β15 (Tβ15) has been linked to an aggressive CaP phenotype and correlated with future tumor recurrence. We hypothesized that Tβ15 may have clinical utility in biological fluids.
Molecular markers of prostate cancer.
• Medicine
• Urologic oncology
• 2006
The current status of PSA testing is reviewed and several candidate protein biomarkers for prostate cancer are discussed, as well as highlighting some recent proteomic discoveries with the potential to supplement or even replace PSA for the diagnosis and prognosis of prostate cancer. Expand
Urine markers in monitoring for prostate cancer
• Medicine
• Prostate Cancer and Prostatic Diseases
• 2010
The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci, and the emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. Expand
Seminar article Molecular markers of prostate cancer
• Medicine
• 2006
The current status of PSA testing is reviewed and several candidate protein biomarkers for prostate cancer are discussed, as well as highlighting some recent proteomic discoveries with the potential to supplement or even replace PSA for the diagnosis and prognosis of prostate cancer. Expand
Molecular Diagnostics in Prostate Cancer
• Medicine
• 2005
Only when research groups use the proposed guidelines for biomarker development, then systematic evaluation and clinical investigation of these biomarkers will gain more insight into their true diagnostic potential. Expand
Molecular markers in the diagnosis of prostate cancer
Recent findings suggest the importance of androgen signaling in disease development and progression and the further understanding of interaction of inflammation, diet, and genetic predisposition will improve risk stratification in the near future. Expand
Elevated thymosin β15 expression is associated with progression and metastasis of non‐small cell lung cancer
• Biology
• 2008
Increased Tβ15 expression correlates with the progression and metastasis of NSCLC, and the relationship between T β15 expression and clinicopathological factors was investigated. Expand
Molecular diagnosis of prostate cancer: are we up to age?
• Medicine
• Seminars in oncology
• 2013
This review will examine the current status of prostate cancer biomarkers with emphasis on emerging biomarkers by evaluating their diagnostic and prognostic potentials. Expand
Markers for Detection of Prostate Cancer
• Medicine
• Cancers
• 2010
Supporting evidence for serum prostate specific antigen (PSA) for detection and also for predicting outcome in prostate cancer is focused on. Expand
APPROACHES TO URINARY DETECTION OF PROSTATE CANCER
• Medicine
• Prostate Cancer and Prostatic Diseases
• 2019
Conceptual and methodological advances in the field will help to drive the development of novel urinary tests that in turn may lead to a shift in the clinical paradigm for prostate cancer diagnosis and management. Expand
Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies
A comparative analysis of the proteins in prostate tissues of the patients operated for hyperplasia or cancer was performed aiming to search for protein diagnostic markers, and an additional protein with a molecular weight of 19 kDa and an isoelectric point of 9.0 was observed in four of the cancer cases. Expand

#### References

SHOWING 1-10 OF 36 REFERENCES
Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study.
It is demonstrated that Tbeta15 staining intensity may be a potentially important marker to identify high-risk patients with moderately differentiated, clinically localized prostate cancer. Expand
Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer
• Biology
• Nature Medicine
• 1996
Transfection of antisense thymosin β15 constructs into rat prostatic carcinoma cells demonstrates that this molecule positively regulates cell motility, a critical component of the metastatic pathway. Expand
Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
• Medicine
• Journal of the Formosan Medical Association = Taiwan yi zhi
• 2003
For patients with advanced prostate cancer receiving ADT, serum CgA may be a useful tumor marker that precedes PSA elevation, which signals ultimate treatment failure and may have clinical implications for implementation of novel therapies. Expand
Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate‐specific antigen levels
The authors compared the risk of biochemical failure after radical prostatectomy (RP) between men with normal PSA levels and men with elevated PSA Levels to find out if normal levels are associated with better outcomes. Expand
Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)
• Medicine
• The Prostate
• 1999
In the European Randomized Study of Screening for Prostate Cancer (ERSPC, Rotterdam region), men aged 55–74 years are screened for prostate cancer by prostate‐specific antigen (PSA) sampling, digitalExpand
Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer
• Medicine
• Cancer
• 1993
The authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and subtracted the incidence of microscopic Stage A cancers too small to ever be clinically significant. Expand
Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease‐free survival after radical prostatectomy
To determine the impact of various preoperative serum prostate specific antigen (PSA) levels in the range from 0.1 to 10 ng/ml on pathological stage and disease‐free survival after radical prostatectomy, a large number of patients were referred for surgery. Expand
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
• Medicine
• Clinical cancer research : an official journal of the American Association for Cancer Research
• 1999
It is confirmed that PSMA is not a specific biomarker for prostate cancer and that a variety of normal and diseased tissue may contribute to the serum levels of PSMA, and found elevated serum PSMA in healthy females, and the levels increased with age. Expand
Thymosin β15 expression in tumor cell lines with varying metastatic potential
• Medicine
• Clinical & Experimental Metastasis
• 2004
Thymosin β15 was upregulated in the highly metastatic mouse lung and human breast cancer cell lines in comparison to the nonmetastatic counterparts, and may be a useful marker to predict metastatic potential of certain human cancers. Expand
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).
• Medicine
• The Journal of urology
• 2003
A significant downward risk migration has occurred over time in Gleason score and PSA, and this shift is most likely attributable to changes in practice patterns with respect to screening and pathological grading. Expand